AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 41 min read$HTFL

Verghese Vikram sold $1.7M of HTFL

Verghese Vikram (Chief Financial Officer) sold 33,416 shares of Heartflow, Inc. (HTFL) at an average of $49.85 ($49.69–$50.60, $1.67M total) across 2 trades over 2026-09-02 to 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Verghese Vikram
Published Sep 4, 2026, 9:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HTFL
Bearish
medium confidence
Mentioned
$HTFL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLBearishLow
01

Why it matters

The CFO's sale reduces insider ownership, which may be interpreted as a lack of confidence, but the modest size limits market impact.

02

Market read

Insider sale news provides a modest bearish cue for HTFL traders.

03

What to watch

Potential upcoming clinical data releases or partnership announcements could offset the negative signal.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑04

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$HTFLBearishMedium confidence
Context

CFO Verghese Vikram sold 33,416 shares for $1.66M via a 10b5‑1 plan, reducing his stake to 221,143 shares.

Expected impact

Short‑term downward pressure; price may dip modestly on the news.

Evidence & confidence

The sale size is modest relative to market cap, but CFO involvement and use of a pre‑arranged plan suggest a neutral‑to‑negative bias.

Market effects

Sector

Minimal; the sale does not affect the broader cardiovascular diagnostics sector.

Regional

None; the filing is company‑specific.

Global

Low; only relevant to investors in HTFL.

Counterpoint

What could challenge this read

The CFO may be liquidating for personal reasons unrelated to company outlook; the sale could be neutral.

Key entities

  • Company
    Heartflow, Inc.

    Medical device company listed on NASDAQ under HTFL.

  • Executive
    Verghese Vikram

    Chief Financial Officer of Heartflow.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HTFL insider trading history →

Related articles

AUG 19
$HTFLMedAI 8/10

Why Heartflow Stock Soared Today

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

aol.com2 min
AUG 15
$HTFLMedAI 8/10

Analysts Are Bullish on Heartflow (HTFL) Stock. Here’s Why

Heartflow Inc. (NASDAQ:HTFL) hit a new all-time high after reporting Q2 revenue growth of 48% to $64.08 million from $43.2 million. The company raised full-year revenue guidance to 40% to 42% growth, targeting $246 million to $250 million. Net loss widened to $15.7 million. Analysts at Stifel and JPMorgan raised price targets to $45.

yahoo.com4 min